A practical reference on GHRH analog: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-08-21 and is reviewed periodically as new material appears.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
CoA-glutathione + glutathione Thus, the two substrates of this enzyme are CoA and glutathione disulfide, whereas its two products are CoA-glutathione and glutathione. This enzyme belongs to the family of oxidoreductases, specifically those acting on a sulfur group of donors with a disulfide as acceptor. The systematic name of this enzyme class is CoA:glutathione-disulfide oxidoreductase. Other names in common use include glutathione-coenzyme A glutathione disulfide transhydrogenase, glutathione-coenzyme A glutathione disulfide transhydrogenase, glutathione coenzyme A-glutathione transhydrogenase, glutathione:coenzyme A-glutathione transhydrogenase, coenzyme A:oxidized-glutathione oxidoreductase, and coenzyme A:glutathione-disulfide oxidoreductase. This enzyme participates in cysteine metabolism and glutathione metabolism.
=== Pattern hair loss === Finasteride is also used to treat male pattern baldness (androgenic alopecia), a condition that develops in up to 80% of Caucasian men aged 70 and over. In the United States, finasteride and minoxidil are the only two FDA-approved drugs for the treatment of male pattern hair loss as of 2017. Treatment with finasteride slows further hair loss. Two meta-analyses found finasteride's efficacy caused about 15% hair regrowth. Specifically oral finasteride was observed to regrow about 18 hair follicles in a square centimeter area of scalp. In comparison a full head of hair usually has 120 hair follicles per square centimeter scalp. Taking finasteride leads to a reduction in scalp and serum DHT levels; by lowering scalp levels of DHT, finasteride can maintain or increase the amount of terminal hairs in the anagen phase by inhibiting and sometimes reversing miniaturization of the hair follicle. Finasteride is most effective on the crown but can reduce hair loss in all areas of the scalp. Finasteride has also been tested for pattern hair loss in women; however, the results were no better than placebo. Finasteride is less effective in the treatment of scalp hair loss than dutasteride.
== Research == A 2014 Cochrane review found insufficient evidence to make a conclusion about its use for the prevention of heart disease. A 2016 Cochrane review concluded that CoQ10 had no effect on blood pressure. A 2021 Cochrane review found "no convincing evidence to support or refute" the use of CoQ10 for the treatment of heart failure. A 2017 meta-analysis of people with heart failure taking 30–100 mg/d of CoQ10 found a 31% lower mortality and increased exercise capacity, with no significant difference in the endpoints of left heart ejection fraction. A 2021 meta-analysis found that CoQ10 was associated with a 31% lower all-cause mortality in HF patients. In a 2023 meta-analysis of older people, ubiquinone had evidence of a cardiovascular effect, but ubiquinol (the reduced form) did not. Although CoQ10 has been studied as a potential remedy to treat purported muscle-related side effects of statin medications, the results were mixed. Although a 2018 meta-analysis concluded that there was preliminary evidence for oral CoQ10 reducing statin-associated muscle symptoms, including muscle pain, muscle weakness, muscle cramps, and muscle tiredness, 2015 and 2024 meta-analysis found that CoQ10 had no effect on statin myopathy.
The most important transport way in Schleswig-Holstein is Kiel Canal, which connect Brunsbüttel on North Sea with Kiel on Baltic Sea. Total cargo of ships reach peaks in 2007 and 2012, after that it continuous decline with 73.8 million tonnes in 2020.
== Uses == Gochujang is used in various dishes such as bibimbap and tteokbokki, and in salads, stews, soups, and marinated meat dishes. Gochujang may make dishes spicier (depending on the capsaicin in the base chili), but also can make them sweeter and smokier.
Sources: en.wikipedia.org
==== India ==== In India, it is a Narcotics prescription-only (NRx) medication used for anxiety disorders, sometimes in combination with other drugs, i.e. the beta blocker propranolol. United Kingdom In the UK, etizolam has been classified as a Class C drug by the May 2017 amendment to The Misuse of Drugs Act 1971 along with several other designer benzodiazepine drugs.
=== 11 July === Eight people were killed by an SAF airstrike in Abu Zabad, West Kordofan. The RSF launched a major attack on El Fasher, seizing the city's main livestock market, the Shalla prison and the headquarters of the Central Reserve Forces before being driven back the next day by the SAF.
== External links == National Center for Voice and Speech's official website Lewcock, Ronald, et al. "Acoustics: The Voice." In Grove Music Online (by subscription)/ http://www.oxfordmusiconline.com/subscriber/article/grove/music/00134pg6
THC is a weak partial agonist at CB1 receptors, while CBD is a CB1 receptor antagonist. The CB1 receptor is found primarily in the brain as well as in some peripheral tissues, and the CB2 receptor is found primarily in peripheral tissues, but is also expressed in neuroglial cells. THC appears to alter mood and cognition through its agonist actions on the CB1 receptors, which inhibit a secondary messenger system (adenylate cyclase) in a dose-dependent manner. Via CB1 receptor activation, THC indirectly increases dopamine release and produces psychotropic effects. CBD also acts as an allosteric modulator of the μ- and δ-opioid receptors. THC also potentiates the effects of the glycine receptors. It is unknown if or how these actions contribute to the effects of cannabis.
Sources: en.wikipedia.org
== S == Saltatory conduction A process in which action potentials "jump" from one node of Ranvier to the next along a myelinated axon, greatly increasing conduction speed. Schizophrenia A severe mental disorder characterized by distortions in thinking, perception, emotions, and behavior. Associated with abnormalities in dopamine signaling and cortical connectivity. Schwann cell A type of glial cell in the peripheral nervous system that forms the myelin sheath around axons, aiding in rapid signal transmission. Second messenger A molecule generated inside a cell in response to a neurotransmitter or hormone binding to a receptor. Examples include cAMP, IP₃, and Ca²⁺. Seizure A sudden, uncontrolled electrical disturbance in the brain that can cause changes in behavior, movements, or consciousness. Selective serotonin reuptake inhibitor (SSRI) A class of antidepressants that increase serotonin levels in the synaptic cleft by blocking its reabsorption into the presynaptic neuron. Semantic memory A type of long-term memory involving general world knowledge, facts, and concepts, distinct from episodic memory. Sensory neuron A neuron that responds to external stimuli such as light, touch, sound, or chemical signals and transmits sensory information to the central nervous system. Sensory cortex A region of the cerebral cortex involved in processing incoming sensory information. Includes the primary somatosensory cortex and adjacent areas.
Kerry-Lynne Donna Findlay (born January 12, 1955) is a Canadian politician and lawyer who served as leader of the Conservative Party of British Columbia from May to September 2026. She had served as a member of Parliament (MP) for South Surrey—White Rock from 2019 to 2025 and Delta—Richmond East from 2011 to 2015 with the federal Conservative Party. Findlay was Associate Minister of National Defence in 2013, and Minister of National Revenue from 2013 to 2015 under Prime Minister Stephen Harper.
=== Animal studies === Multiple animal studies have investigated the biological activity of D-ribose-L-cysteine in models of oxidative stress and metabolic injury. These studies have reported that D-ribose-L-cysteine supplementation increases intracellular and tissue glutathione levels, improves antioxidant enzyme activity, and reduces markers of oxidative damage in rodents. In several experimental models, D-ribose-L-cysteine demonstrated equal or greater glutathione-enhancing effects compared with N-acetylcysteine, though these findings are limited to preclinical settings.
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.